Logo

Melanoma Diagnostics

Castle Biosciences Q1 Revenues Grow 18 Percent

The Friendswood, Texas-based molecular diagnostics company reported revenues of $26.9 million in Q1 2022, up from $22.8 million a year ago.

Castle Biosciences Q4 Revenues Grow 45 Percent

The molecular diagnostics company said it delivered 33 percent more DecisionDx-Melanoma test results in Q4 2021 than in the previous year's fourth quarter.

Castle Biosciences Receives New York State Approval for DecisionDx DiffDx-Melanoma Test

The gene expression profile assay is meant to aid dermatopathologists in characterizing difficult-to-diagnose melanocytic lesions.

Castle Biosciences Awarded VA Supply Contract for Melanoma Test

The company said the contract will provide greater access to its DecisionDx-Melanoma gene expression profile test for veterans and active duty military.

Reporting 27 Percent Q3 Jump, Myriad Outlines Three-Pronged Plan for Diversifying Revenue Base
Premium

After reporting a 27 percent increase in its fiscal third quarter revenues, Myriad Genetics this week outlined three strategic directives for diversifying its revenue base, including growing sales of its existing tests in the US, launching new tests and companion diagnostics in a
Breaking News
The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.